(一)股东大会召开的时间：2025 年 08 月 15 日 (二)股东大会召开的地点：广州市番禺区化龙镇国贸大道南 47 号公司一号楼二 楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 169 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 161,223,461 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 55.0498 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长向彬先生主持，大会采用现场投票 和网络投票相结合的表决方式进行表决，会议的召开和表决方式符《公司法》和 证券代码：603309 证券简称：维力医疗 公告编号：2025-052 广州维力医疗器械股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 ...

格隆汇8月15日丨维力医疗(603309.SH)在互动平台表示，公司暂时没有布局脑科介入导管领域，但公司 有颅脑引流管等输入神经外科器械类相关产品布局，同时公司将积极关注行业发展趋势，结合公司发展 战略，择机布局脑科其他类医疗器械新领域。 ...

Group 1 - The core viewpoint of the articles highlights the recent movements of social security funds in the stock market, with 16 new stocks being added to their portfolio in the second quarter [1] - A total of 384 companies have disclosed their semi-annual reports, revealing the actions of institutional investors through the top ten circulating shareholders [1] - Social security funds appeared in 57 stocks, with 16 new positions, 15 increased holdings, 15 reduced holdings, and 11 stocks where the holding amount remained unchanged [1] Group 2 - Among the newly established stocks, the highest number of social security fund appearances in the top ten circulating shareholders is in Su Shi Testing, with three funds holding a total of 14.86 million shares, accounting for 2.94% of circulating shares [1] - The stock with the highest holding ratio among the new positions is Zhong Chumei, with a holding ratio of 3.45%, followed by Beiding Co., Ltd. at 3.16% [1] - The stock with the largest holding amount among the new positions is Satellite Chemical, with 20.17 million shares held, followed by Su Shi Testing and Zhongyuan Expressway with 14.86 million shares and 13 million shares, respectively [1] Group 3 - In terms of performance, 15 of the newly established stocks reported year-on-year net profit growth, with the highest increase being 496.60% for Xin Qiang Lian, which achieved a net profit of 399.61 million yuan [2] - Other companies with significant net profit growth include Ta Pai Group and Guo Mai Culture, with increases of 92.47% and 80.38%, respectively [2] - A detailed list of newly established stocks by social security funds includes various companies across different industries, such as Zhong Chumei in basic chemicals and Beiding Co., Ltd. in home appliances [2]

Group 1 - The stock price of Weili Medical is reported at 14.78 yuan, down by 0.16 yuan from the previous trading day, with an intraday high of 15.04 yuan and a low of 14.72 yuan, and a trading volume of 89,168 lots, amounting to 1.32 billion yuan [1] - The company specializes in the research, production, and sales of medical devices, covering various fields such as anesthesia, respiratory, and urology, with main products including tracheal intubation, laryngeal masks, and urinary catheters [1] - A temporary shareholders' meeting is scheduled for August 15 to review 15 proposals, including the repurchase and cancellation of restricted stock, changes to registered capital, and amendments to the company's articles of association, which will be held at the company's headquarters in Panyu District, Guangzhou, with participation options available both on-site and online [1]

Core Viewpoint - The company, Weili Medical, is currently facing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Weili Medical's stock closed at 14.78 yuan, down 1.07%, with a rolling PE ratio of 18.47 times and a total market capitalization of 4.329 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, and sales of medical catheters in areas such as anesthesia, urology, respiration, and hemodialysis [1]. - The latest financial report for the first half of 2025 shows the company achieved a revenue of 745 million yuan, a year-on-year increase of 10.19%, and a net profit of 121 million yuan, up 14.17%, with a gross profit margin of 45.04% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Weili Medical at the 41st rank within the industry [1][2]. - The industry shows a wide range of PE ratios, with the highest being 20.62 times for Antu Biology and the lowest at 11.18 times for Jiuan Medical [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为了借助专业投资机构的产业资源和产业投资管理优势，落实公司战略发展规划，广州维力医疗器械股 份有限公司（以下简称"公司"）与橡栎医林投资（苏州）合伙企业（有限合伙）、苏州天使投资引导基 金（有限合伙）、橡栎莲芰(广州)创业投资基金合伙企业(有限合伙)于2025年6月23日签署了《维智医航 （苏州）医疗产业投资合伙企业（有限合伙）合伙协议》，公司拟作为有限合伙人参与设立维智医航 （苏州）医疗产业投资合伙企业（有限合伙）（以下简称"维智医航"），维智医航拟募资规模为人民币 15,000万元，公司拟认缴出资人民币3,750万元，占总认缴出资规模的25%，资金来源为自有资金。（具 体内容详见公司2025年6月24日披露于《中国证券报》、《上海证券报》、《证券时报》及上海证券交 易所网站（www.sse.com.cn）的《关于参与设立产业投资基金的公告》（2025-041））。 一、对外投资基本情况 董事会 2025年6月24日，公司参与设 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603309 证券简称：维力医疗 公告编号：2025-051 备案日期：2025年8月7日 广州维力医疗器械股份有限公司 关于参与设立产业投资基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、对外投资基本情况 为了借助专业投资机构的产业资源和产业投资管理优势，落实公司战略发展规划，广州维力医疗器械股 份有限公司（以下简称"公司"）与橡栎医林投资（苏州）合伙企业（有限合伙）、苏州天使投资引导基 金（有限合伙）、橡栎莲芰(广州)创业投资基金合伙企业(有限合伙)于2025年6月23日签署了《维智医航 （苏州）医疗产业投资合伙企业（有限合伙）合伙协议》，公司拟作为有限合伙人参与设立维智医航 （苏州）医疗产业投资合伙企业（有限合伙）（以下简称"维智医航"），维智医航拟募资规模为人民币 15,000万元，公司拟认缴出资人民币3,750万元，占总认缴出资规模的25%，资金来源为自有资金。（具 体内容详见公司2025年6月24日披露于《中国证券报》、《上海证券报》、 ...

2025 年 6 月 24 日，公司参与设立的产业基金维智医航（苏州）医疗产业投 资合伙企业（有限合伙）已完成工商登记手续。（具体内容详见公司 2025 年 6 月 27 日披露于《中国证券报》、《上海证券报》、《证券时报》及上海证券交 易所网站（www.sse.com.cn）的《关于参与设立产业基金的进展公告》（2025-042））。 证券代码：603309 证券简称：维力医疗 公告编号：2025-051 一、对外投资基本情况 为了借助专业投资机构的产业资源和产业投资管理优势，落实公司战略发展 规划，广州维力医疗器械股份有限公司（以下简称"公司"）与橡栎医林投资（苏 州）合伙企业（有限合伙）、苏州天使投资引导基金（有限合伙）、橡栎莲芰(广 州)创业投资基金合伙企业(有限合伙)于 2025 年 6 月 23 日签署了《维智医航（苏 州）医疗产业投资合伙企业（有限合伙）合伙协议》，公司拟作为有限合伙人参 与设立维智医航（苏州）医疗产业投资合伙企业（有限合伙）（以下简称"维智 医航"），维智医航拟募资规模为人民币 15,000 万元，公司拟认缴出资人民币 3,750 万元，占总认缴出资规模的 25%，资金来源为自 ...

Core Insights - The article highlights the recent movements of social security funds in the stock market, revealing that 15 new stocks were added to their portfolio in the second quarter [1] - A total of 238 companies have released their semi-annual reports, with social security funds appearing in 40 stocks, indicating significant institutional activity [1] Summary by Category New Investments - Social security funds initiated positions in 15 new stocks during the second quarter, with the highest number of funds appearing in Su Shi Testing, where three funds are listed among the top ten shareholders [1] - The stock with the highest proportion held by social security funds among new investments is Zhong Chumei, with a holding ratio of 3.45%, followed by Beiding Co., Ltd. at 3.16% [1] Holdings and Changes - In terms of shareholding volume, the stock with the largest number of shares held by social security funds is Satellite Chemical, with 20,169,300 shares, followed by Su Shi Testing and Zhongyuan Expressway with 14,862,000 shares and 13,000,100 shares, respectively [1][2] - The article provides a detailed table listing the new stocks acquired by social security funds, including their stock codes, names, number of funds involved, shareholding volume, and industry classifications [2] Performance Metrics - Among the new investments, 14 companies reported year-on-year net profit growth, with the highest increase recorded by Xin Qiang Lian at 496.60% [2] - Other notable companies with significant net profit growth include Ta Pai Group and Guo Mai Culture, with increases of 92.47% and 80.38%, respectively [2]

Core Viewpoint - Vili Medical's stock closed at 14.9 yuan, up 2.83%, with a rolling PE ratio of 18.62, marking a new low in 410 days, and a total market value of 4.364 billion yuan [1] Company Summary - Vili Medical specializes in the research, production, and sales of medical catheters in fields such as anesthesia, urology, respiratory care, and hemodialysis [1] - The company's main products include tracheal intubation, laryngeal masks, bronchial intubation, visual bronchial intubation, tracheostomy tubes, anesthesia masks, artificial noses, anesthesia breathing circuits, electronic analgesia pumps, urinary catheters, urinary bags, antibacterial urinary catheters, temperature-measuring urinary catheters, drainage bags, male urinary catheters, precision urinary bags, minimally invasive dilation drainage kits, guidewires, balloon dilation catheters, ureteral dilators, ureteral guiding sheaths, stone retrieval baskets, ureteral stents, and ureteral catheters [1] Financial Performance - For the first half of 2025, Vili Medical reported operating revenue of 745 million yuan, a year-on-year increase of 10.19%, and a net profit of 121 million yuan, up 14.17%, with a gross profit margin of 45.04% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Vili Medical at 40th in the industry ranking [1] - The industry average PE (TTM) is significantly higher than Vili Medical's current PE of 18.62, indicating potential undervaluation [2]